It is also likely that these results may translate to patients with NASH and even advanced fibrosis, based on the metabolic benefits observed in these patients with a glucagon-like peptide 1 (GLP-1) receptor agonist, such as subcutaneous semaglutide [55,163]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.